BR112019002945A2 - terapia de combinação para o tratamento de câncer pancreático - Google Patents
terapia de combinação para o tratamento de câncer pancreáticoInfo
- Publication number
- BR112019002945A2 BR112019002945A2 BR112019002945-1A BR112019002945A BR112019002945A2 BR 112019002945 A2 BR112019002945 A2 BR 112019002945A2 BR 112019002945 A BR112019002945 A BR 112019002945A BR 112019002945 A2 BR112019002945 A2 BR 112019002945A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pancreatic cancer
- cancer treatment
- combination therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378322P | 2016-08-23 | 2016-08-23 | |
| US62/378,322 | 2016-08-23 | ||
| PCT/US2017/047985 WO2018039211A1 (en) | 2016-08-23 | 2017-08-22 | Combination therapy for the treatment of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019002945A2 true BR112019002945A2 (pt) | 2019-05-21 |
Family
ID=59762090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019002945-1A BR112019002945A2 (pt) | 2016-08-23 | 2017-08-22 | terapia de combinação para o tratamento de câncer pancreático |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10933058B2 (enExample) |
| EP (1) | EP3503922B1 (enExample) |
| JP (2) | JP7579636B2 (enExample) |
| KR (1) | KR20190039951A (enExample) |
| CN (1) | CN109641058A (enExample) |
| AU (1) | AU2017316618A1 (enExample) |
| BR (1) | BR112019002945A2 (enExample) |
| CA (1) | CA3034259A1 (enExample) |
| IL (1) | IL264589A (enExample) |
| MX (1) | MX2019002121A (enExample) |
| WO (1) | WO2018039211A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018039211A1 (en) * | 2016-08-23 | 2018-03-01 | Genentech, Inc. | Combination therapy for the treatment of pancreatic cancer |
| WO2020014650A1 (en) * | 2018-07-13 | 2020-01-16 | Memorial Sloan Kettering Cancer Center | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer |
| BR112022007603A2 (pt) * | 2019-10-22 | 2022-07-19 | Chemistryrx | Métodos para o tratar hiperplasia epidermica congênita |
| CN115243719B (zh) * | 2020-03-06 | 2024-09-13 | 北京先通生物医药技术有限公司 | CTB006与Ponatinib联合应用 |
| CN116509852A (zh) * | 2023-04-30 | 2023-08-01 | 兰州大学第二医院 | 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用 |
| CN116585312A (zh) * | 2023-04-30 | 2023-08-15 | 兰州大学第二医院 | 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US9532987B2 (en) * | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015175846A2 (en) * | 2014-05-16 | 2015-11-19 | University Of Massachusetts | Treating chronic myelogenous leukemia (cml) |
| WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
| US10792284B2 (en) * | 2015-02-12 | 2020-10-06 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| WO2018039211A1 (en) * | 2016-08-23 | 2018-03-01 | Genentech, Inc. | Combination therapy for the treatment of pancreatic cancer |
-
2017
- 2017-08-22 WO PCT/US2017/047985 patent/WO2018039211A1/en not_active Ceased
- 2017-08-22 EP EP17761408.8A patent/EP3503922B1/en active Active
- 2017-08-22 MX MX2019002121A patent/MX2019002121A/es unknown
- 2017-08-22 AU AU2017316618A patent/AU2017316618A1/en not_active Abandoned
- 2017-08-22 JP JP2019510651A patent/JP7579636B2/ja active Active
- 2017-08-22 KR KR1020197004431A patent/KR20190039951A/ko not_active Ceased
- 2017-08-22 CN CN201780051187.XA patent/CN109641058A/zh active Pending
- 2017-08-22 CA CA3034259A patent/CA3034259A1/en not_active Abandoned
- 2017-08-22 BR BR112019002945-1A patent/BR112019002945A2/pt not_active IP Right Cessation
-
2019
- 2019-01-31 IL IL264589A patent/IL264589A/en unknown
- 2019-02-22 US US16/283,203 patent/US10933058B2/en active Active
-
2021
- 2021-02-19 US US17/180,522 patent/US12419879B2/en active Active
-
2024
- 2024-08-01 JP JP2024125935A patent/JP2024170398A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10933058B2 (en) | 2021-03-02 |
| EP3503922B1 (en) | 2022-10-26 |
| CA3034259A1 (en) | 2018-03-01 |
| MX2019002121A (es) | 2019-08-12 |
| AU2017316618A1 (en) | 2019-02-07 |
| WO2018039211A1 (en) | 2018-03-01 |
| EP3503922A1 (en) | 2019-07-03 |
| JP2024170398A (ja) | 2024-12-10 |
| US20190175576A1 (en) | 2019-06-13 |
| IL264589A (en) | 2019-02-28 |
| JP7579636B2 (ja) | 2024-11-08 |
| US12419879B2 (en) | 2025-09-23 |
| KR20190039951A (ko) | 2019-04-16 |
| JP2019526559A (ja) | 2019-09-19 |
| CN109641058A (zh) | 2019-04-16 |
| US20210283120A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009571A2 (pt) | Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| BR112016014481A2 (pt) | tratamento de câncer utilizando combinações de inibidores de erk e raf | |
| CY1117440T1 (el) | Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido | |
| BR112016007946A2 (pt) | combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
| BR112013007681A2 (pt) | uso terapêutico de um agonista trl e terapia de combinação | |
| BR112016028964A2 (pt) | métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX378872B (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
| MX391720B (es) | Terapia combinada para tratar cáncer. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112017003186A2 (pt) | composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| BR112023025916A2 (pt) | Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção | |
| BR112021022602A2 (pt) | Métodos para tratamento de urticária espontânea crônica com o uso de um inibidor de tirosina quinase de bruton | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2685 DE 21-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |